- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07949643
Operator-Assisted Oscilla Audiometry as a Basis for Hearing Aid Fitting (The Oscilla Validation Study)
Validation of Operator-Assisted Oscilla Audiometry as a Diagnostic Tool and Basis for Hearing Aid Fitting in Adults With Uncomplicated Hearing Loss: A Blinded Non-Inferiority Randomised Controlled Trial
The purpose of this study is to find out whether hearing tests performed with the Oscilla A60 audiometer, where the patient largely tests themselves with minimal staff assistance, are accurate enough to be used for diagnosing hearing loss and as the sole basis for fitting hearing aids. Adults referred for their first hearing aids at Aalborg University Hospital will have their hearing tested both with the Oscilla audiometer and by a trained audiology assistant at the same visit. Participants are then randomly assigned to receive hearing aids fitted based on either the Oscilla hearing test or the audiology assistant's hearing test. The main questions are: (1) Do the Oscilla results agree with the audiology assistant's results for both air-conduction and bone-conduction hearing thresholds? (2) Do participants fitted based on the Oscilla test report a hearing benefit that is not worse than that of participants fitted based on the standard test, two months after fitting?
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Demand for audiometric testing in public hearing clinics is increasing due to population ageing. Operator-assisted automated audiometry may expand capacity, but its use as the sole basis for hearing aid prescription, and its accuracy for bone-conduction (BC) thresholds, has not been established. This single-site study at the Department of Audiology, Aalborg University Hospital (locations in Aalborg and Hobro) enrols 268 first-time hearing aid users with uncomplicated, symmetric sensorineural hearing loss.
At Visit 1, all participants undergo both Oscilla A60 audiometry (air conduction [AC] 250-8000 Hz; BC 250-4000 Hz) and standard manual audiometry by an audiology assistant (reference standard), in randomised order. Agreement between methods is assessed with Bland-Altman analysis against pre-specified acceptance criteria (95% CI of bias within ±5 dB; 95% limits of agreement within ±15 dB for AC and ±20 dB for BC). After confirmation of eligibility, participants are randomised 1:1, stratified by hearing loss severity (PTA-4 ≤45 vs >45 dB HL) and location, to hearing aid fitting based on the Oscilla audiogram or the audiology assistant audiogram. All participants are fitted bilaterally with BTE/RIC hearing aids to the NAL-NL2 target, verified with automated real-ear measurements (within ±5 dB). Volume control and app connectivity are disabled until the two-month follow-up. The primary patient-reported outcome is the change in SSQ12 total score from baseline to two months post-fitting, with a non-inferiority margin of -0.81 points. Secondary outcomes are IOI-HA, daily hearing aid use (data logging) and SSQ12 subscales. The study is a clinical investigation under Article 82 of Regulation (EU) 2017/745.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lene D Siggaard, MD, PhD
- Numéro de téléphone: +45 20633492
- E-mail: lene.dahl@rn.dk
Sauvegarde des contacts de l'étude
- Nom: Camilla L Sørensen, Cand. med.
- E-mail: c.lorents@rn.dk
Lieux d'étude
-
-
-
Aalborg, Danemark, 9000
- Department of Audiology, Aalborg University Hospital
-
Contact:
- Camilla L Sørensen, Cand. med.
- E-mail: c.lorents@rn.dk
-
Contact:
- Lene D Siggaard, MD, PhD
- Numéro de téléphone: +4520633492
- E-mail: lene.dahl@rn.dk
-
Hobro, Danemark, 9500
- Hearing Clinic, Aalborg University Hospital
-
Contact:
- Camilla L Sørensen, Cand. med.
- E-mail: c.lorents@rn.dk
-
Contact:
- Lene D Siggaard, MD, PhD
- Numéro de téléphone: +4520633492
- E-mail: lene.dahl@rn.dk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults (≥18 years) referred for first-time hearing aid fitting at the Department of Audiology, Aalborg University Hospital
- Uncomplicated sensorineural hearing loss as defined by the Danish national clinical guidelines
- Hearing thresholds exceeding 20 dB HL at two or more frequencies in the range 0.5-4 kHz
- Pure-tone average (PTA-4; 0.5, 1, 2, 4 kHz) ≥30 dB HL in the better ear
- Symmetric hearing loss (PTA-4 difference between ears ≤15 dB)
- Word discrimination score ≥25% (DANTALE I at PTA + 40 dB HL)
- Danish native speaker
- No prior hearing aid experience
- Able to complete questionnaires online or on paper
- Written informed consent
Exclusion Criteria:
- Air-conduction thresholds exceeding 80 dB HL at two or more frequencies
- Air-bone gap >15 dB at one or more frequencies below 1 kHz
- Fluctuating hearing loss (e.g., Ménière's disease) or ongoing ototoxic medication
- Ear surgery (ear canal, middle ear or inner ear) within the past 12 months
- Hearing loss classified as complicated according to national clinical guidelines
- Visual or motor impairment precluding independent use of the Oscilla system
- Candidates for in-the-ear hearing aids only (all participants are fitted with BTE or RIC hearing aids)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Oscilla-based fitting
Hearing aids fitted bilaterally to NAL-NL2 targets based on the Oscilla A60 audiogram, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: Paired audiometry and Oscilla-based hearing aid fitting). |
At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order. Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the Oscilla A60 audiogram as the sole audiometric basis, verified with auto-REM (within ±5 dB of target). Other names: Oscilla A60 Diagnostic Audiometer. |
|
Comparateur actif: Manual audiometry-based fitting
Hearing aids fitted bilaterally to NAL-NL2 targets based on the audiogram obtained by a qualified audiology assistant, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: paired audiometry and manual audiometry-based hearing aid fitting). |
At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order. Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the audiology assistant audiogram, verified with auto-REM (within ±5 dB of target). Standard clinical practice. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Agreement between Oscilla A60 and manual audiometry for air-conduction thresholds
Délai: Visit 1 (Week 0)
|
Bland-Altman mean difference (Oscilla minus manual) and 95% limits of agreement in dB, plus mean absolute difference, at 0.5, 1, 2 and 4 kHz separately. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±15 dB. Both ears included, clustering handled with a mixed-effects model. |
Visit 1 (Week 0)
|
|
Agreement between Oscilla A60 and manual audiometry for bone-conduction thresholds
Délai: Visit 1 (Week 0)
|
As above for bone-conduction thresholds at 0.5, 1, 2 and 4 kHz. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±20 dB. |
Visit 1 (Week 0)
|
|
Change in SSQ12 total score
Délai: Baseline (Week 0) and 2 months after hearing aid fitting
|
Speech, Spatial and Qualities of Hearing Scale, 12-item version; total score = mean of 12 items, range 0-10, higher = better. Non-inferiority if the lower bound of the two-sided 95% CI for the between-group difference in change (Oscilla minus control) is above -0.81 points. |
Baseline (Week 0) and 2 months after hearing aid fitting
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
IOI-HA total score
Délai: 2 months after hearing aid fitting
|
International Outcome Inventory for Hearing Aids, Danish version; 7 items scored 1-5, total range 7-35, higher = better outcome. Compared between groups |
2 months after hearing aid fitting
|
|
Daily hearing aid use
Délai: From hearing aid fitting to 2 months after fitting
|
Mean daily hearing aid usage time in hours/day from the hearing aid data log, compared between groups |
From hearing aid fitting to 2 months after fitting
|
|
Change in SSQ12 subscale scores
Délai: Baseline (Week 0) and 2 months after hearing aid fitting
|
Change in the speech, spatial and qualities subscale scores (each range 0-10, higher = better) |
Baseline (Week 0) and 2 months after hearing aid fitting
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Lene D Siggaard, MD, PhD, Department of Otolaryngology, Head- and Neck Surgery and Audiology, Aalborg University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- F2026-115
- Regional Innovation Fund (Autre subvention/numéro de financement: North Denmark Region)
- Danish Medicines Agency (Identificateur de registre: 16-0302-225)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Pseudonymised individual participant data may be shared upon reasonable request after publication, subject to approval under the GDPR and Danish data protection law and a data processing agreement.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .